Literature DB >> 1714497

PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.

U Haberkorn1, L G Strauss, A Dimitrakopoulou, R Engenhart, F Oberdorfer, H Ostertag, J Romahn, G van Kaick.   

Abstract

Forty-four patients with recurrent colorectal carcinoma were examined prior to a combination of conventional photon radiotherapy (40 Gy) and neutron therapy (10 Gy). Twenty-one of these underwent a PET examination after photon therapy and 12 also were studied after the end of combined therapy. CEA plasma levels were measured from blood samples taken immediately before the PET study. A significant decrease in FDG uptake despite good palliative results were observed in only 50% of the patients. This may be explained by inflammatory reactions caused by radiation injury. Inflammation and metabolically active residual tumor tissue cannot be distinguished. It is concluded that an observation interval longer than 6 mo may more effectively detect residual tumor activity. In 14 of 41 examinations, an increased FDG uptake was associated with a normal CEA value, and in only two cases were normal FDG uptake values and increased CEA levels found, suggesting that PET is more sensitive than the measurements of CEA plasma levels for tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714497

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

3.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Clinical applications of molecular imaging in sarcoma evaluation.

Authors:  Rodney J Hicks; Guy C Toner; Peter F M Choong
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

5.  Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.

Authors:  Manuel Rodríguez-Garrido; Cristina Asensio-del-Barrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

6.  FDG-PET in infectious lesions: The detection and assessment of lesion activity.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; Y Akashi; S Murayama; K Nakamura; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

7.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

8.  Carbon-11-methionine positron emission tomography imaging of chordoma.

Authors:  Hong Zhang; Kyosan Yoshikawa; Katsumi Tamura; Kenji Sagou; Mei Tian; Tetsuya Suhara; Susumu Kandatsu; Kazutoshi Suzuki; Shuji Tanada; Hirohiko Tsujii
Journal:  Skeletal Radiol       Date:  2004-07-28       Impact factor: 2.199

9.  Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.

Authors:  S Yasuda; S Raja; K F Hubner
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.